Given that pathological phenotypes of amyloid beta (Aβ) deposition and the phosphorylation of Tau are hallmarks in AD22, we first investigated whether the level of phosphorylated Tau can be changed by chronic cerebral hypoperfusion to study the pathway by which cerebral hypoperfusion contributes to AD. This evidence concerns the gene MAPT and Alzheimer disease.